The COVID-19 pandemic has proven to be complex and multifaceted, and that is why the Novacyt Group are constantly innovating. This latest portfolio of patented assays to identify Single Nucleotide Polymorphisms (SNPs) critical to each variant, is called SNPsig® - one of the first commercially available range of assays for variant detection. The SNPsig® portfolio for detecting variants complements Novacyt’s existing range of PCR COVID-19 assays and enables a funnelling of proven expertise into the dynamic world of variant detection.
KEY FEATURES:
- Can be used as reflex testing as only extracted RNA is needed
- Streamlined workflow for easy use with readily prepared Mastermix
- Open platform compatibility
- No cold chain shipping
- Results in under 2 hours
KEY BENEFITS:
- An alternative to next generation sequencing and S gene target failure (SGTF), it enables scientists to analyse and monitor these specific genomic mutations
- Pivotal in the role of screening for SARS-CoV-2 Variants for the purpose of genomic surveillance studies